Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Withdrawn × Thyroxine × Clear all

Phase

Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Postoperative Complications 1 Neoplasms 1 Hypothyroidism 1

Interventions

Oxaliplatin 5 Leucovorin 4 Fluorouracil 4 Gemcitabine 3 pirarubicin 2 liposomal doxorubicin 2 Surgical Procedures, Operative 2 Radiation 2 Paclitaxel 2 Neoadjuvant Therapy 2 Folfox protocol 2 vocimagene amiretrorepvec 1 taxane 1 sulindac sulfone 1 remdesivir 1 pembrolizumab 1 nimotuzumab 1 methylnaltrexone 1 lenvatinib 1 carbon-11 acetate 1 bavituximab 1 alovudine 1 aflibercept 1 Thyroxine 1 Therapeutics 1 Temozolomide 1 Taxes 1 Tacrolimus 1 Standard of Care 1 Sirolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02548715 2022-07-13

LSHT

University of Alberta

Phase 2/3 Withdrawn

Hypothyroidism, Neoplasms, Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡